Table of Contents
International Journal of Molecular Imaging
Volume 2016 (2016), Article ID 2568031, 12 pages
http://dx.doi.org/10.1155/2016/2568031
Review Article

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation

1Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
2Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

Received 16 June 2016; Accepted 29 August 2016

Academic Editor: Francesca Pons

Copyright © 2016 Nghi C. Nguyen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Howlader, A. M. Noone, M. Krapcho et al., SEER Cancer Statistics Review, 1975–2013, National Cancer Institute, Bethesda, Md, USA, based on November 2015 SEER data submission, posted to the SEER web site, 2016.
  2. G. D. Roodman, “Mechanisms of bone metastasis,” The New England Journal of Medicine, vol. 350, no. 16, pp. 1655–1664, 2004. View at Publisher · View at Google Scholar
  3. C. Parker, S. Nilsson, D. Heinrich et al., “Alpha emitter radium-223 and survival in metastatic prostate cancer,” The New England Journal of Medicine, vol. 369, no. 3, pp. 213–223, 2013. View at Publisher · View at Google Scholar
  4. L. M. E. Lien, B. Tvedt, and D. Heinrich, “Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride,” International Journal of Urological Nursing, vol. 9, no. 1, pp. 3–13, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. D. P. Petrylak, C. M. Tangen, M. H. A. Hussain et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1513–1520, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Buchali, H.-J. Correns, M. Schuerer, D. Schnorr, H. Lips, and K. Sydow, “Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma,” European Journal of Nuclear Medicine, vol. 14, no. 7-8, pp. 349–351, 1988. View at Publisher · View at Google Scholar · View at Scopus
  7. O. Sartor, “Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease,” Reviews in Urology, vol. 6, supplement 10, pp. S3–S12, 2004. View at Google Scholar
  8. O. Sartor, P. Hoskin, and Ø. S. Bruland, “Targeted radio-nuclide therapy of skeletal metastases,” Cancer Treatment Reviews, vol. 39, no. 1, pp. 18–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Sgouros, J. C. Roeske, M. R. McDevitt et al., “MIRD pamphlet No. 22 (Abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy,” Journal of Nuclear Medicine, vol. 51, no. 2, pp. 311–328, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. O. S. Bruland, S. Nilsson, D. R. Fisher, and R. H. Larsen, “High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra: adjuvant or alternative to conventional modalities?” Clinical Cancer Research, vol. 12, no. 20, pp. 6250s–6257s, 2006. View at Publisher · View at Google Scholar
  11. S. Nilsson, R. H. Larsen, S. D. Fossa et al., “First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases,” Clinical Cancer Research, vol. 11, no. 12, pp. 4451–4459, 2005. View at Google Scholar
  12. J. A. Carrasquillo, J. A. O'Donoghue, N. Pandit-Taskar et al., “Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 9, pp. 1384–1393, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Nilsson, L. Franzén, C. Parker et al., “Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases,” Clinical Genitourinary Cancer, vol. 11, no. 1, pp. 20–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Nilsson, P. Strang, A. K. Aksnes et al., “A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer,” European Journal of Cancer, vol. 48, no. 5, pp. 678–686, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Parker, N. J. Vogelzang, O. Sartor et al., “3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA,” Journal of Clinical Oncology, vol. 33, supplement 7, abstract 195, 2015, Proceedings of the Genitourinary Cancers Symposium. View at Google Scholar
  16. Xofigo® (Radium Ra 223 Dichloride) Injection [Prescribing Information], Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ, USA, 2013.
  17. T. D. Dan, H. B. Eldredge-Hindy, J. Hoffman-Censits et al., “Hematologic toxicity of concurrent administration of radium-223 and next-generation antiandrogen therapies,” American Journal of Clinical Oncology, 2015. View at Publisher · View at Google Scholar
  18. C. C. Parker, S. Pascoe, A. Chodacki et al., “A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer,” European Urology, vol. 63, no. 2, pp. 189–197, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Sonpavde, G. R. Pond, W. R. Berry et al., “Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy,” Urologic Oncology: Seminars and Original Investigations, vol. 30, no. 5, pp. 607–613, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. O. Sartor, R. Coleman, S. Nilsson et al., “Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial,” The Lancet Oncology, vol. 15, no. 7, pp. 738–746, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. R. F. Hobbs, H. Song, C. J. Watchman et al., “A bone marrow toxicity model for 223Ra alpha-emitter radiopharmaceutical therapy,” Physics in Medicine and Biology, vol. 57, no. 10, pp. 3207–3222, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Lassmann and D. Nosske, “Dosimetry of 223Ra-chloride: dose to normal organs and tissues,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 2, pp. 207–212, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Nilsson, “Radionuclide therapies in prostate cancer: integrating radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer,” Current Oncology Reports, vol. 18, no. 2, article 14, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Morris, C. S. Higano, H. I. Scher et al., “Effects of radium-223 dichloride with docetaxel versus docetaxel on prostate specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration resistant prostate cancer (CRPC) and bone metastases (mets): a phase 1/2a clinical trial,” Journal of Clinical Oncology, vol. 33, supplement 7, abstract 202, 2015. View at Google Scholar
  25. S. E. Finkelstein, J. M. Michalski, J. M. O'Sullivan et al., “External Beam Radiation Therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases from the ALSYMPCA trial,” Journal of Clinical Oncology, vol. 53, supplement 7, abstract 182, 2015. View at Google Scholar
  26. S. Nilsson, L. Franzén, C. Parker et al., “Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study,” The Lancet Oncology, vol. 8, no. 7, pp. 587–594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Nome, E. Hernes, T. V. Bogsrud, T. Bjøro, and S. D. Fosså, “Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223,” Scandinavian Journal of Urology, vol. 49, no. 3, pp. 211–217, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Saad, J. Carles, S. Gillessen et al., “Radium-223 in an international early access program (EAP): effects of concomitant medication on overall survival in metastatic castration resistant prostate cancer (mCRCP) patients,” Journal of Clinical Oncology, vol. 33, supplement, abstract 5034, 2015, Proceedings of the ASCO Annual Meeting. View at Google Scholar
  29. A. O. Sartor, D. C. Fernandez, M. J. Morris et al., “Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting,” Journal of Clinical Oncology, vol. 33, supplement 7, abstract 253, 2015. View at Google Scholar
  30. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Gillessen, A. Omlin, G. Attard et al., “Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015,” Annals of Oncology, vol. 26, no. 8, pp. 1589–1604, 2015. View at Publisher · View at Google Scholar
  32. C. J. Ryan, S. Shah, E. Efstathiou et al., “Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response,” Clinical Cancer Research, vol. 17, no. 14, pp. 4854–4861, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Messiou, G. Cook, A. H. M. Reid et al., “The CT flare response of metastatic bone disease in prostate cancer,” Acta Radiologica, vol. 52, no. 5, pp. 557–561, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. J. Morris, A. Molina, E. J. Small et al., “Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results,” Journal of Clinical Oncology, vol. 33, no. 12, pp. 1356–1363, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. A. R. Padhani, A. Makris, P. Gall, D. J. Collins, N. Tunariu, and J. S. de Bono, “Therapy monitoring of skeletal metastases with whole-body diffusion MRI,” Journal of Magnetic Resonance Imaging, vol. 39, no. 5, pp. 1049–1078, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. F. E. Lecouvet, A. Larbi, V. Pasoglou et al., “MRI for response assessment in metastatic bone disease,” European Radiology, vol. 23, no. 7, pp. 1986–1997, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. F. E. Lecouvet, J. N. Talbot, C. Messiou, P. Bourguet, Y. Liu, and N. M. de Souza, “Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group,” European Journal of Cancer, vol. 50, no. 15, pp. 2519–2531, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. C.-T. Shen, Z.-L. Qiu, T.-T. Han, and Q.-Y. Luo, “Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis,” Clinical Nuclear Medicine, vol. 40, no. 2, pp. 103–110, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. D. C. Bortot, B. J. Amorim, G. C. Oki et al., “18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 11, pp. 1730–1736, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Chakraborty, A. Bhattacharya, U. K. Mete, and B. R. Mittal, “Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma,” Clinical Nuclear Medicine, vol. 38, no. 8, pp. 616–621, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Iagaru, E. Mittra, D. W. Dick, and S. S. Gambhir, “Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases,” Molecular Imaging and Biology, vol. 14, no. 2, pp. 252–259, 2012. View at Publisher · View at Google Scholar
  42. National Comprehensive Cancer Network (NCCN), Prostate Cancer Updates, Version 3, 2016, https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  43. A. Takalkar, S. Adams, and V. Subbiah, “Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone,” Experimental Hematology & Oncology, vol. 3, article 23, 2014. View at Publisher · View at Google Scholar
  44. R. Coleman, A.-K. Aksnes, B. Naume et al., “A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease,” Breast Cancer Research and Treatment, vol. 145, no. 2, pp. 411–418, 2014. View at Publisher · View at Google Scholar · View at Scopus